Takeda announces a voluntary withdrawal for 650 IU VONVENDI® due to misprinted labels showing incorrect expiration dates.

The new study explored how new training opportunities based on a peer-to-peer model might be received by U.S. physical therapists at hemophilia treatment centers.

Explore groundbreaking research from Yale School of Medicine on von Willebrand factor (VWF) and its role in bleeding disorders.

The BLA submission is supported by positive safety and efficacy data from an ongoing global phase 3 clinical trial known as BASIS

The National Bleeding Disorders Foundation and the American Thrombosis & Hemostasis Network Partnering to Create Data Commons.

The data were presented at the recent 65th American Society of Hematology (ASH) Annual Meeting and Exposition.

Sickle cell disease is a rare condition that includes a group of inherited blood disorders associated with an abnormality in the hemoglobin protein.

Due to supply constraints, Novo Nordisk will be unable to provide the 8 mg vial of NovoSeven® RT from January until mid-2024. Importantly, the overall supply of NovoSeven® RT is expected to remain intact as other vial sizes are available.